Randall Harris, MD, PhD

Research Honor

Fellow, American Association for the Advancement of Science, 2008, for research showing that inhibition of the inducible cyclooxygenase-2 (COX-2) gene has significant anti-neoplastic effects against major forms of cancer.

• M.D., University of Nebraska 1983
• Ph.D., Genetics, North Carolina State University 1974
• M.S., Genetics, University of Nebraska 1971
• Board Certifications: Clinical Pathology, Public Health

• PUBHEPI 2410: Epidemiology in Public Health
• PUBHEPI 5438: Cardiovascular Disease Epidemiology
• PUBHEPI 6411: Biological Basis of Public Health
• PUBHEPI 6437: Cancer Epidemiology
• PUBHEPI 7412: Principles and Procedures for Human Clinical Trials

Books

Harris RE.  Global Epidemiology of Cancer, Jones & Bartlett, 2015.

Harris RE. Epidemiology of Chronic Disease: Global Perspectives, Jones & Bartlett, 2012.

Harris RE.  Inflammation in the Pathogenesis of Chronic Diseases: the COX-2 Controversy, Springer, 2007.

Harris RE.  COX-2 Blockade in Cancer Prevention and Therapy.  Humana Press, 2003.

Articles

Kennedy BM, Harris RE (2018).  Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer.  Inflammopharmacology. 2018 May 7.  doi: 10.1007/s10787-018-0489-6.

Harris RE, Beebe J, Schwartzbaum J (2020).  Chemoprevention of breast cancer by lipoxygenase and cyclooxygenase inhibitors.   World Academy of Sciences Journal 2020; 2(1), 14-18,  https://doi.org/10.3892/wasj.2020.34.

Harris RE, Casto BC, Harris ZM.  Cyclooxygenase-2 and the inflammogenesis of breast cancer.  World Journal of Clinical Oncology 5(4): 677-692, 2014.

Harris RE, Beebe J, Al Shafie GA.  Reduction in cancer risk by selective and non-selective cyclooxygenase 2 (COX-2) inhibitors.  J Exp Pharm, 4, 91-96,   2012.  

Harris RE. Cyclooxygenase-2 (COX-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammo-pharmacology. 17:1-13, 2009.

Harris RE, Beebe-Donk J, Alshafie GA. Similar reductions in the risk of human colon cancer by selective and non-selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 8 (237): Aug 14, 2008.

Harris RE, Beebe-Donk J, Alshafie GA. Reduced risk of human lung cancer by selective cyclooxygenase-2 (COX-2) blockade: results of a case control study. International Journal of Biological Sciences, 3(5): 328-334, 2007

Harris RE. COX-2 and the inflammogenesis of cancer. Subcellular Biochemistry, 42: 193-212, 2007.

Harris RE, Beebe-Donk JD, Alshafie GA. Cancer chemoprevention by selective cyclooxygenase-2 (COX-2) blockade: results of case control studies. Subcellular Biochemistry, 42: 83-126, 2007.

Harris RE; Beebe-Donk J; Alshafie GA. Reduction in the risk of human breast cancer by COX-2 inhibitors. Biomed Central (BMC). Cancer, 6:27, 2006.

Harris, RE, Beebe-Donk J.  Aspirin, ibuprofen, and other nonsteroidal anti-inflammatory drugs (NSAIDs) in cancer prevention: a critical review (Review).  Oncology Reports 13 (4), 559-583, 2005.

Harris RE.  Does the dose make the poison?  Science 308; 203, 2005.

Harris RE, Sparks A, McTiernan A, Anderson G, White E, Chlebowski RT,  Frid D, Jackson R.  Inverse association of breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative.  Cancer Research 63: 6096-6101, 2003.

Harris RE, Beebe-Donk J, Schuller HM.  Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncology Reports 9: 693-395, 2002.

Harris RE, Namboodiri KA, Beebe-Donk, J.  Inverse association of malignant melanoma and non-steroidal anti-inflammatory drugs (NSAIDs) in women.  Oncology Reports 8: 655-657, 2001.

Harris RE, Alshafie GA, Abou-Issa H, Seibert K.  Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.  Cancer Research 60: 2101-2103, 2000.

Harris RE, Kasbari S, Farrar WB.  Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer.  Oncology Reports 6:71-73, 1999.

Joarder FS, Abou-Issa H, Robertson FM, Parrett ML, Alshafie G, and Harris RE.  Growth arrest of DMBA-induced mammary carcinogenesis with ibuprofen treatment in female sprague-dawley rats.  Oncology Reports 4:1271-1273, 1997.

Harris RE, Namboodiri KK, Farrar WB.  Nonsteroidal anti-inflammatory drugs and breast cancer.  Epidemiology 7:203-205, 1996.

Harris RE, Namboodiri KK, Farrar WB.  Epidemiologic study of non-steroidal anti-inflammatory drugs and breast cancer.  Oncology Reports 2: 591-592, 1995.

Harris RE, Zang EA, Anderson JI, Wynder EL.  Race and sex differences in lung cancer risk associated with cigarette smoking.  Intl J Epidemiology 22(4): 592-599, 1993.

Harris RE, Namboodiri KK, Wynder EL.  Breast cancer risk: Effects of estrogen replacement therapy and body mass.  J Natl Cancer Inst 84 (20): 1575-1582, 1992.

Harris RE, Hebert JR, Wynder EL.  Cancer risk in male veterans utilizing the veterans administration medical system.  Cancer 64: 1160-1168, 1989.

Harris RE, Wynder EL.  Breast cancer and alcohol consumption: a study in weak associations.  J Am Med Assoc 259(19): 2867-2871, 1988.

Harris RE, Lynch, HT, Guirgis HA.  Familial breast cancer: risk to the contralateral breast.  J Natl Cancer Inst 60: 955-960, 1978.